Trials / Completed
CompletedNCT03384472
Malaria Genetic Surveillance in Cambodia
Integrating Genetic Epidemiology as an Intensified Surveillance Tool Into the National Centre for Parasitology, Entomology and Malaria Control of Cambodia
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 185 (actual)
- Sponsor
- University of Oxford · Academic / Other
- Sex
- All
- Age
- 6 Months
- Healthy volunteers
- Not accepted
Summary
This study is to determine the prevalence and geographical distribution of antimalarial drug resistance-linked genetic mutations in clinical P. falciparum infections in Cambodia
Detailed description
This is a prospective observational study of patients with clinical Plasmodium falciparum infection using parasite DNA from point-of-care fingerprick dried blood spot samples as well as a short survey on patient demographics, employment, travel, and mobile phone use to study P. falciparum parasite genotypes, population characteristics, and gene flow patterns. On inclusion in the study and before standard treatment is administered, dried blood spots (DBS) will be obtained through fingerprick blood sampling from patients, with three blood spots on one piece of filter paper being obtained from each patient. Each blood spot will contain \~20µl of blood, for a total of \~60µl of blood being collected from each patient for the study. In order to have a greater understanding of the possible sites of malaria transmission and to relate genetic diversity to geographic location, patients or their parents/guardians will also be asked a short set of questions on demographics, their places of residence and work, recent mobile phone use, and their history of travel in the last 2 months. As some of this information can be sensitive, during the consent process the patient will be given the option of not providing some or all of this information without needing to provide a reason. This is explained on the patient information sheet. For those who do not want to provide information, this will be documented in the survey form. A duplicate of the sample barcode will be placed on this same form, so the information therein can be matched with the relevant blood spot and its related genetic data, while retaining sample anonymity.
Conditions
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2017-02-01
- Completion
- 2017-02-01
- First posted
- 2017-12-27
- Last updated
- 2022-05-24
Source: ClinicalTrials.gov record NCT03384472. Inclusion in this directory is not an endorsement.